PREVIEW

New Three-Drug Therapy Offers Hope for Advanced Breast Cancer. A new drug combination could double survival time for advanced breast cancer patients. Researchers have developed a therapy targeting a common form of aggressive breast cancer, offering hope for prolonged life. A trial involving 325 patients across 28 countries tested a three-drug combo, including two targeted drugs—palbociclib and inavolisib. The drugs target the PI3K protein, a driver of cancer growth, alongside hormone therapy. Patients on the therapy experienced 15 months without disease progression, compared to 7.3 months in the placebo group. 46% of patients on the three-drug therapy showed no disease progression at 18 months versus 21% in the placebo group. Anne Lury, diagnosed with stage 2 breast cancer in 2007, shared her journey with inavolisib after prior treatments stopped working. Despite fatigue, Anne had few side effects and credits the trial for extending her life. Prof. Nick Turner described this therapy as a “huge breakthrough,” marking progress for people with HR-positive breast cancer. Over 56,000 cases of breast cancer are diagnosed annually in the UK, with nearly 11,500 deaths each year. While unapproved in the UK, the U.S. FDA recently greenlit the three-drug therapy for certain advanced breast cancers. “An extra eight months without disease progression means more time for people to be with their families,” says Breast Cancer Now’s Dr. Simon Vincent.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT